Morgan Stanley Upgrades Charles River Laboratories While Downgrading IQVIA Holdings
On June 17, Morgan Stanley upgraded Charles River Laboratories (CRL) to Overweight with a price target of $220 and downgraded IQVIA Holdings (IQV) to Equal-weight with a reduced target of $200. The move comes as both companies operate in the contract research organization sector, but CRL is seen benefiting more from increased biotech funding.
Topics: biopharma industry Charles River Laboratories CROs IQVIA Holdings Morgan Stanley